Tafamidis treatment delays structural and functional changes of the left ventricle in patients with transthyretin amyloid cardiomyopathy

René Rettl; Christopher Mann; Franz Duca; Theresa-Marie Dachs; Christina Binder; Luciana Camuz Ligios; Lore Schrutka; Daniel Dalos; Matthias Koschutnik; Carolina Donà; Andreas A. Kammerlander; Dietrich Beitzke; Christian Loewe; Silvia Charwat‐Resl; Christian Hengstenberg; Johannes Kästner; Roza Badr Eslam; Diana Bonderman

doi:10.1093/ehjci/jeab226

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Tafamidis delays myocardial amyloid progression in ATTR-CM patients, resulting in structural, functional, and clinical benefits compared to the natural course. Serial CMR including measurement of ECV may be appropriate for disease-specific therapy monitoring.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Rettl et al. (2021) studied this question.

synapsesocial.com/papers/69eff8fdbce9831ba4f734ff https://doi.org/10.1093/ehjci/jeab226

View Full Paper

Ask AI

Bookmark

Share

Tafamidis treatment delays structural and functional changes of the left ventricle in patients with transthyretin amyloid cardiomyopathy

Ask about this paper

Abstract

Discussion

Cite This Study

Tafamidis treatment delays structural and functional changes of the left ventricle in patients with transthyretin amyloid cardiomyopathy

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading